Sponsored

Double bonanza: Creso eyes OTC listing; Halucenex gets new psilocybin supplies

Source: Miss Nuchwara Tongrit, Shutterstock

Summary

  • Creso Pharma’s acquisition target Halucenex has secured an additional stockpile of pharmaceutical-grade psilocybin.
  • Halucenex is confident that the new synthetic psilocybin would lessen the risks to its clinical trial schedule.
  • Creso also announced that it is seeking a US OTC listing driven by increasing interest from investors in North America.
  • The cannabis player anticipates the OTC listing will unlock considerable value for its existing shareholders.

ASX-listed global pharma player Creso Pharma Limited (ASX:CPH, FRA:1X8) has been grabbing the spotlight of late on the back of multiple significant announcements.

On 23 March 2021, the Company updated the market about its intent to dual list on the US OTCQB (OTC) market. Besides the dual listing update, Creso Pharma also announced that its acquisition target, Halucenex Life Sciences, had obtained a new supply for pharmaceutical-grade synthetic psilocybin from its Canadian manufacturing partner.

Halucenex secures new stockpile for psilocybin

Halucenex received an additional supply of 700mg of psilocybin for use in its future clinical trial plan, adding to the 11.6g secured earlier.

The psychedelics company finalised the deal with its manufacturing partner, the only pharmaceutical-grade synthetic psilocybin manufacturer in Canada.

Halucenex, the target acquisition of Creso Pharma Group, is a life science development player engaged in the research, development, and licensing of novel psychedelic molecules for the worldwide pharmaceutical and nutraceutical markets.

MUST READ: Creso Pharma (ASX:CPH) seals a transformative deal to foray into psychedelics space

Source: CPH Announcement, 23 March 2021

Additional batch of psilocybin lowers risks to clinical trial schedule

Securing an additional batch of psilocybin is a significant development for Halucenex, and the Company is confident that this new stock will reduce risks to the clinical trial schedule.

With the new batch, Halucenex has a 12.3g accessible volume of synthetic psilocybin, allowing the Company to increase the number of participants in the Phase II trial. This confirms that the Phase II and Phase III clinical trial participants would be treated with the same Good Manufacturing Practice (GMP)-certified batch of synthetic psilocybin for tracking.

The new GMP-certified supply will allow Halucenex to conduct GMP formulations in the new delivery methods like microdoses, capsules, nasal and intravenous (IV) solution. Besides, the GMP formulations provide stability and validation of the delivery, which is crucial for any clinical trial.

The GMP certification also implies that the Company does not need further certifications for its supply from the regulators.

DO READ: Creso Pharma’s acquisition target Halucenex readies for PTSD trial

Planned OTC listing

In another exciting update, Creso Pharma brought to light its proposed dual listing on the OTC market in the US. The decision to advance the dual listing initiative was aided by the burgeoning interest from North American investors. Creso notified that the listing is a part of the strategy to increase global recognition of its operations in the cannabis and psychedelics medicines space.

The recent acquisition of Halucenex and Creso’s planned expansion into the US cannabis market (currently dependent on federal legalisation) is important for several North American investors.

Moreover, Creso Pharma will maintain regular disclosure in line with the reporting requirements of its primary market, the ASX, where the ordinary shares of the Company will continue to trade under the symbol “CPH”.

CPH anticipates the OTC listing would unlock significant value for its existing shareholders by helping North American investors be a part of Creso’s story. This will also allow easier comparisons to US and Canadian listed competitors operating in the cannabis and psychedelics space.

Notably, the Company continues to expand its global reach and advance prospective opportunities in the US cannabis sector. Creso also seeks to expand its business to psychedelics development with the acquisition of Halucenex.

The Company expects the US OTC listing to take place during the second quarter of CY2021. Besides, it will provide an update when the trading ticker has been given, and the listing timing is confirmed.

Management Commentary

Non-executive Chairman Adam Blumenthal commented:

Mr Blumenthal also added that Creso is highly excited about its anticipated OTC listing. CPH has a growing global footprint, and the OTC will offer a platform to enhance the Company’s visibility to a comprehensive base of US investors, especially as cannabis moves ahead on the road to legalisation.

He added that the Company was looking forward to updating the market on the OTC listing process in due course.

Adding to this, Bill Fleming, Founder & CEO of Halucenex, commented:

ALSO READ: Creso Pharma’s (ASX:CPH) subsidiary Mernova bags three new purchase orders

Creso Pharma anticipates that OTC listing will offer significant shareholder value and provide the Company access to one of the world’s leading investment markets.

On 31 March 2021, CPH shares closed at A$0.200.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK